$32.13
+2.12 (+7.06%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ASMB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
22 interventional · 7 with posted results
Held by 9 tracked-famous managers (Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, Schonfeld Strategic Advisors LLC, CITADEL ADVISORS LLC, Qube Research & Technologies Ltd, +4 more) · FINRA short interest 15.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus InfectionNCT07762027Proportion of subjects with adverse events (AEs), premature treatment discontinuation and abnormal laboratory results.Randomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: ABI-6250, ABI-6250 | Chronic Hepatitis D Infection | 80 | Jun 2027 | ≤ 315 d | 2026-08-13 |
| A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital HerpesNCT06385327Area Under the Plasma Concentration Time Curve (AUC) of ABI-5366Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: ABI-5366, ABI-5366 Placebo | Recurrent Genital Herpes Simplex Type 2 | 115 | 2026-02-03actual | — | 2026-03-30 |
| A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital HerpesNCT06698575Area Under the Plasma Concentration Time Curve, (AUC) of ABI-1179Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: ABI-1179, ABI-1179 Placebo | Recurrent Genital Herpes Simplex Type 2 | 103 | 2026-01-19actual | — | 2026-03-23 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy ParticipantsNCT06740474Proportion of subjects with AEs, premature treatment discontinuation due to AEs and abnormal laboratory resultsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: ABI-6250, Placebo | Hepatitis Delta Virus, Hepatitis D | 40 | 2025-07-08actual | — | 2025-12-04 |
| A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus InfectionNCT06384131To assess the safety and tolerability of ABI-4334 in subjects with cHBV following 28-day multiple oral dosesRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: ABI-4334, Placebo | Chronic Hepatitis B | 20 | 2025-04-15actual | — | 2025-07-23 |
| A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus InfectionNCT05414981Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AEs, and abnormal laboratory resultsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: ABI-H3733, Placebo | Chronic Hepatitis B | 31 | 2023-04-24actual | — | 2023-06-29 |
| A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy SubjectsNCT05569941Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AEs, and abnormal laboratory resultsRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: ABI-4334 Tablet, ABI-4334 Placebo | Chronic Hepatitis B | 54 | 2023-04-12actual | — | 2023-09-13 |
| A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B InfectionNCT04820686results2023-11-14Number of Participants With One or More Adverse Events (AEs)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: VBR, AB-729, SOC NrtI | Chronic Hepatitis B | 65 | 2023-03-30actual | — | 2023-11-14 |
| A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus InfectionNCT04781647results2023-10-06Number of Participants With an Adverse EventRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study ABI-H0731-203 was terminated early by the study Sponsor for strategic reasons to prioritize research and development efforts on finite and curative HBV therapies. | Drug: ABI-H0731, ETV · Biological: Peg-IFNα | Chronic Hepatitis B | 54 | 2022-12-02actual | — | 2023-10-06 |
| A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus InfectionNCT04398134results2022-08-26Percentage of Participants With Adverse EventsRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study stopped due to a safety signal of drug-induced liver injury in subjects receiving 2158 | Drug: ABI-H2158, Placebo, Entecavir (ETV) | Chronic Hepatitis B | 88 | 2021-10-14actual | — | 2022-09-15 |
| A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B PatientsNCT03780543results2023-02-17Sustained Viral Response (SVR) at 24 Weeks Off TreatmentNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI) | Chronic Hepatitis B | 92 | 2021-04-26actual | — | 2023-04-19 |
| A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase InhibitorsNCT04454567results2022-10-20Number of Participants With an Adverse EventRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study stopped due to a change in the Sponsor's overall development strategy from treatment of chronic disease to finite, curative treatments, and is based partially on the advice and feedback from experts and regulators. | Drug: ABI-H0731, Placebo, NrtI | Chronic Hepatitis B | 2 | 2021-04-08actual | — | 2022-10-20 |
| ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative ColitisNCT03923478Incidence of Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: ABI-M201, Placebo | Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate | 15 | 2021-01-20actual | — | 2021-03-19 |
| A Study to Evaluate the Mass Balance Absorption and AME of VBRNCT04637139Mass Balance: Cumulative Amount of [14C] Radiolabel Excreted in Urine up to the Last Sampling Interval (Ae-urine, 14C)Open-label · Treatment | Phase 1 | Completed | Drug: Vebicorvir (VBR) | Chronic Hepatitis B | 6 | 2020-12-22actual | — | 2021-01-12 |
| A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis BNCT03714152Number of healthy volunteers and patients with chronic HBV infection with treatment-related adverse events as assessed by CTCAE v4.0.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ABI-H2158, Placebo for ABI-H2158 | Chronic Hepatitis B | 80 | 2020-11-23actual | — | 2021-01-27 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy AdultsNCT04271592Number of Participants with One or More Adverse EventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: ABI-H3733 Liquid Oral Dosage Form, ABI-H3733 Solid Oral Dosage Form, Placebo to ABI-H3733 Liquid Oral Dosage Form, Placebo to ABI-H3733 Solid Oral Dosage Form | Chronic Hepatitis B | 120 | 2020-11-03actual | — | 2021-01-27 |
| A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy AdultsNCT04142762Area under the plasma concentration time curve (AUC) of ABI-H2158Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive | Chronic Hepatitis B | 80 | 2020-01-12actual | — | 2020-03-04 |
| A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy AdultsNCT04083716Area under the plasma concentration time curve (AUC) of ABI-H2158: Relative Bioavailability and Food EffectRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: ABI-H2158 Reference Formulation, ABI-H2158 Test Formulation | Chronic Hepatitis B | 15 | 2019-10-05actual | — | 2019-11-29 |
| A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B InfectionNCT03576066results2021-01-28Change in Mean log10 Serum HBsAg From Baseline (Day 1) to Week 24 on ABI-H0731 + SOC NUC as Compared to Placebo + SOC NUCRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ABI-H0731, SOC NUC, Placebo Oral Tablet | Chronic Hepatitis B | 73 | 2019-07-05actual | — | 2021-02-17 |
| A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)NCT03577171results2021-01-28Change in Mean log10 HBV DNA From Baseline (Day 1) to Week 12 or Week 24 on ABI H0731 + SOC ETV as Compared to Placebo + SOC ETVRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ABI-H0731, SOC ETV, Placebo Oral Tablet | Chronic Hepatitis B | 25 | 2019-06-21actual | — | 2021-01-28 |
| A Study in Healthy Volunteers and Patients With Chronic Hepatitis BNCT02908191Number of healthy volunteers and patients with chronic HBV infection with treatment-related adverse events as assessed by CTCAE v4.0.Randomized · Single-masked · Treatment | Phase 1 | Completed | Drug: ABI-H0731, Placebo for ABI-H0731, Entecavir, Tenofovir disoproxil fumarate, Pegasys, Nucleos(t)ide | Chronic Hepatitis B | 86 | 2018-03-31actual | — | 2019-04-04 |
| Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis BNCT03109730Number of patients with chronic HBV infection with treatment-related adverse events and laboratory abnormalities as assessed by CTCAE v4.0.Randomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: ABI-H0731, Placebo for ABI-H0731, Entecavir, Tenofovir Disoproxil Fumarate, Pegasys | Chronic Hepatitis B | 38 | 2018-03-31actual | — | 2018-07-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19